Hero

Make VABYSMO your FIRST CHOICE.

Animated illustration of retinal drying effect of Vabysmo.

Faster* and greater*

drying with fewer

injections vs.

aflibercept1-3

Animated clock illustrating the dosing durability of Vabysmo, with key intervals marked up to 16 weeks.

Flexible dosing and
extended durability1,2,4

An animated gif of two upward arrows indicating the dual-pathway inhibition mechanism of action of Vabysmo.

Powerful dual-pathway

inhibition5-8

*Based on post hoc, exploratory analysis with nominal P-value statistical analysis not adjusted for multiple testing (nominal P-value <0.05 vs. aflibercept 2.0 mg Q8W), no formal statistical conclusions can be drawn. Primary endpoint of Phase III studies was non-inferiority in BCVA vs. aflibercept 2.0 mg Q8W for nAMD and DME, and aflibercept 2.0 mg Q4W for RVO.

References
  1. Khanani AM, et al. Ophthalmology. 2024;19:S0161-6420(24)00134-9.
  2. Wong TY, et al. Ophthalmology. 2024;131(6):708-723. 
  3. Chaudhary V, et al. Presented at ARVO 2023.
  4. Tadayoni R, et al. Presented at Angiogenesis 2024, presentation available at medically.roche.com. 
  5. Regula JT, et al. EMBO Mol Med. 2016;8:1265–88. 
  6. Heier JS, et al. Lancet. 2022;399:729–40. 
  7. Wykoff CC, et al. Lancet. 2022;399:741–55. 
  8. VABYSMO®. SmPC https://go.roche.com/Vabysmo_SmPC Accessed May 2024.